29202-13-9

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 99-98-9 4-amino-N,N-dimethylaniline 
• 7032-25-9 (E)-N-(2-pyridylmethylene)aniline 

Downstream Products

• 7032-25-9 (E)-N-(2-pyridylmethylene)aniline 
• 99-98-9 4-amino-N,N-dimethylaniline 
• 1337878-34-8 [Zn(N₁,N₁-dimethyl-N₄-(pyridin-2-ylmethylene)benzene-1,4-diamine)Cl₂] 
• 52688-60-5 (N¹,N¹-dimethyl-N⁴-(pyridin-2-ylmethyl)benzene-1,4-diamine) 
• 1351363-71-7 JS₄₈ 
• 1351363-68-2 JS₄₇ 
• 1351363-65-9 JS₄₆ 
• 1351363-71-7 C₃₅H₃₆ClN₃Rh⁽¹⁺⁾*F₆P^(1-) 
• 1351363-68-2 C₂₉H₃₂ClN₃Rh⁽¹⁺⁾*F₆P^(1-) 
• 1351363-65-9 C₂₄H₃₀ClN₃Rh⁽¹⁺⁾*F₆P^(1-) 

Relevant academic research and scientific papers

Design of a Tris-Heteroleptic Ru(II) Complex with Red-Light Excitation and Remarkably Improved Photobiological Activity

Ru(II)-polypyridyl complexes are of increasing interest in photodynamic therapy (PDT) due to their easily tunable photophysical and photochemical properties. However, short-wavelength absorption of Ru(II)-polypyridyl complexes has limited their penetration depth in PDT. Herein, the series of Ru(II)-polypyridyl complexes 1-4 was designed by replacing one bipyridine in [Ru(bpy)3]Cl2 with Schiff bases (iminopyridine or iminoquinoline analogues) to achieve red-shifted absorption of Ru(II)-polypyridyl photosensitizers. To further shift the absorption to longer wavelength and improve the photobiological activity of Ru(II)-polypyridyl complexes, the three tris-heteroleptic Ru(II) complexes 5-7 with benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine (dppn) as a ligand were designed to achieve long-lived intraligand (3IL) excited states. Cytotoxicity data against A549 and HepG2 cells revealed that complex 7 showed extraordinarily high cytotoxicity under 650 nm irradiation, resulting in IC50 values of 56 and 63 nM with exceptionally large phototoxicity index (PI) values of 763 and 613, respectively. Thus, the resulting complex 7 with considerable red-light photocytotoxicity and high PI values shows a promising potential for therapeutic applications, which represents a new scaffold of Ru(II)-polypyridyl photosensitizers for PDT in the therapeutic window . This study delivers a rational strategy for the design of tris-heteroleptic Ru(II) complexes as promising photosensitizers for cancer therapy. ?

Effect of substituents on the 13C chemical shifts of the azomethine carbon atom of N-(phenyl substituted)pyridine-3- and -2-aldimines

13C chemical shifts of the azomethine carbon atom for N-(phenyl substituted)pyridine-3-aldimines, 3-Py-CH=N-C6H4-X, and N-(phenyl substituted)pyridine-2-aldimines, 2-Py-CH=N-C6H4-X, having a wide rang

Targeting metal-Aβ aggregates with bifunctional radioligand [11C]L2-b and a fluorine-18 analogue [18F]FL2-b

Interest in quantifying metal-Aβ species in vivo led to the synthesis and evaluation of [11C]L2-b and [18F]FL2-b as radiopharmaceuticals for studying the metallobiology of Alzheimer's disease (AD) using positron emission tomography (PET) imaging. [11C]L2-b was synthesized in 3.6% radiochemical yield (nondecay corrected, n = 3), >95% radiochemical purity, from the corresponding desmethyl precursor. [18F]FL2-b was synthesized in 1.0% radiochemical yield (nondecay corrected, n = 3), >99% radiochemical purity, from a 6-chloro pyridine precursor. Autoradiography experiments with AD positive and healthy control brain samples were used to determine the specificity of binding for the radioligands compared to [11C]PiB, a known imaging agent for β-amyloid (Aβ) aggregates. The Kd for [11C]L2-b and [18F]FL2-b were found to be 3.5 and 9.4 nM, respectively, from those tissue studies. Displacement studies of [11C]L2-b and [18F]FL2-b with PiB and AV-45 determined that L2-b binds to Aβ aggregates differently from known radiopharmaceuticals. Finally, brain uptake of [11C]L2-b was examined through microPET imaging in healthy rhesus macaque, which revealed a maximum uptake at 2.5 min (peak SUV = 2.0) followed by rapid egress (n = 2).

Studies of electronic effects of modified pyridine-imine ligands utilized in cobalt-catalyzed meta-selective Diels-Alder reactions

The regioselectivity of cobalt-catalyzed Diels-Alder reactions can be controlled by the choice of ligands on the cobalt center. Ligands of the pyridine-imine type favor the formation of the 1,3-disubstitution pattern on the dihydroaromatic product. The investigation was aimed to elucidate the factors for controlling the regioselectivities and reactivity induced by electronic effects of the pyridine-imine ligands in the cobalt-catalyzed Diels-Alder reaction. For that, electron-withdrawing as well as electron donating substituents were introduced in the 4-position on the pyridine moiety and on the 4′-position of the aniline derivative used in the imine subunit of the ligands. In close synergy DFT calculations and the comparison with experimental results proved that electronic variation of the substituents at both positions have a negligible influence on the regioselectivity. However, the kinetic data for the cobalt-catalyzed Diels-Alder reactions revealed that there are great differences in the lengths of the induction periods when different cobalt pyridine-imine complexes are applied. These results could be elucidated by conductivity experiments showing that ionic homoleptic complexes Co(L) 22+/CoBr42- are in equilibrium with their corresponding neutral heteroleptic complexes of type Co(L)Br2 in solution. The equilibrium position depends on the electronic characteristics of the pyridine-imine ligands (L), thereby influencing the length of the induction period.

COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS

Provided herein are compositions and methods for the treatment and analysis of neurological disorders. In particular, provided herein are small molecules targeted to amyloid-β (Aβ ) or metal-Aβ species for the treatment, diagnosis, or study of neurological conditions such as Alzheimer's disease (AD) and other diseases and conditions.

Small molecule modulators of copper-induced Aβ aggregation

(Chemical Equation Presented) Our design of bifunctional metal chelators as chemical probes and potential therapeutics for Alzheimer's disease (AD) is based on the incorporation of a metal binding moiety into structural frameworks of Aβ aggregate-imaging

Designing multistep transformations using the Hammett equation: Imine exchange on a Copper(I) template

Herein, we quantify how imine exchange may be used to selectively transform one metalloorganic structure into another. A series of imine exchange reactions were studied, involving a set of 4-substituted anilines, their 2-pyridylimines and 1,10-phenanthrolyl-2,9-diimines, as well as the copper complexes of these imine ligands. Electron-rich anilines were found to displace electron-poor anilines in all cases. Linear free energy relationships (LFERs) were discovered connecting the electron-donating or -withdrawing character of the 4-substituent of an aniline, as measured by the Hammett σpara parameter, to that aniline's ability to compete with unsubstituted aniline to form imines. The quality of these LFERs allowed for quantitative predictions: to obtain the desired degree of selectivity in an imine exchange between anilines A and B, the required σpara differential could be predicted using a variant of the Hammett equation, log(KAB) = ρ(σA - σB). We validated this methodology by designing and executing a three-step transformation of a series of copper(I)-containing structures. Each step proceeded in predictably high yield, as calculated from σ differentials. At each step in the series of transformations, macrocyclic structures could be created or destroyed through the selection of mono- or di-amines as subcomponents. The same methodology could be used to predict the formation of a diverse dynamic library of helicates from a set of four aniline precursors, as well as the collapse of this library into one helicate upon the addition of a fifth aniline.